全文获取类型
收费全文 | 87篇 |
免费 | 6篇 |
国内免费 | 1篇 |
专业分类
基础医学 | 2篇 |
临床医学 | 12篇 |
内科学 | 14篇 |
外科学 | 1篇 |
综合类 | 33篇 |
预防医学 | 18篇 |
药学 | 10篇 |
中国医学 | 3篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 1篇 |
2022年 | 2篇 |
2021年 | 2篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 1篇 |
2014年 | 8篇 |
2013年 | 11篇 |
2012年 | 5篇 |
2011年 | 4篇 |
2010年 | 3篇 |
2009年 | 14篇 |
2008年 | 3篇 |
2007年 | 7篇 |
2006年 | 3篇 |
2005年 | 1篇 |
2004年 | 4篇 |
2003年 | 1篇 |
2002年 | 11篇 |
2001年 | 3篇 |
2000年 | 1篇 |
排序方式: 共有94条查询结果,搜索用时 15 毫秒
51.
Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program. 相似文献
52.
目的:研究2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFL)的患者的临床特点及其与血清尿酸(SUA)的关系。方法:将113例住院T2DM患者根据有无合并非酒精性脂肪肝分为合并脂肪肝组和非脂肪肝组,记录患者身高、体重、腰围、臀围,进行空腹血糖(FBG)、血总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、血清尿酸(SUA)、空腹胰岛素(FINS)测定,计算体重指数(BMI)、腰臀比(WHR)、胰岛素抵抗指数(HOMA-IR)。对两组的一般临床资料进行统计学分析。结果:2型糖尿病合并脂肪肝组BMI、WHR、FINS、HOMA-IR、LDL-C、TG、SUA较非脂肪肝组升高(P<0.05),而FBG、TC、HDL-C两组差别无显著性(P>0.05)。脂肪肝患者中高尿酸血症患者比例较高,男性脂肪肝患者的尿酸高于女性脂肪肝患者。结论:2型糖尿病合并脂肪肝组血脂异常、胰岛素抵抗更明显,SUA的水平显著升高。 相似文献
53.
Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program. 相似文献
54.
55.
56.
老张多年前就发现有糖尿病,一直也没有什么特别不舒服,对于治疗,想起了就吃药,忙起来就忘了服药,更不用说检查了。可这几天老张有点烦,老觉得眼前有 相似文献
57.
淀粉酶升高是诊断急性胰腺炎的重要血清学指标,但淀粉酶升高不应只考虑胰腺疾病。该文报道一例淀粉酶持续升高1年余的66岁男性患者,大疱性类天疱疮并糖尿病3年,8个月前因治疗大疱性类天疱疮时发现血清淀粉酶升高,波动于556~1106 U/L。血脂肪酶波动于62~73 U/L,尿淀粉酶波动于553~1162 U/L。计算肾淀粉酶清除率/肌酐清除率为0.8% (<1%)。该例无胃肠道症状,腹部彩色多普勒超声(彩超)和CT增强显示胰腺未见异常,甲状腺和唾液腺彩超未见异常,口腔科会诊排除唾液腺疾病,最后确诊为巨淀粉酶血症。随访8个月,患者一直无腹部不适,淀粉酶呈现下降趋势,但仍高于正常水平。该病例提示如果患者血淀粉酶持续升高,无动态变化特征,且不伴腹部不适和脂肪酶升高时,要警惕巨淀粉酶血症。 相似文献
58.
59.
慢性粒细胞白血病患者血脂变化的初步研究 总被引:1,自引:0,他引:1
目的:了解慢性粒细胞白血病(CML)患者的血脂变化规律。方法:收集中山医科大一院1997年9月-2000年6月的初治CML病例,共127例。检测TC、TG、HDL、LDL、apoA1、apoB和apoA1/apoB。结果:CML加速期和急变期患者的TC、TG、HDL、LDL、apoA1、apoB较正常或CML慢性期患者明显降低(P<0.05),TG和apoA1/apoB则明显升高(P<0.05),若经治疗达到完全缓解(CR)则各指标恢复正常水平(P>0.05)。加速期和急变期之间、慢性期与正常对照之间各指标无明显区别(P>0.05),急性变中急淋变与急粒变无明显差异(P>0.05)。结论:检测血脂有可能成为慢性粒细胞白血病患者病情监测、追踪随访,特别是加速期和急变期患者疗效判断的一项有重要意义的敏感指标。 相似文献
60.
糖尿病口服降糖药的治疗进展 总被引:1,自引:0,他引:1
随着经济的增长,人们生活水平的提高与生活方式的改变,我国糖尿病的患病率不断增加。虽然目前暂时还看不到根治糖尿病的时间,但可喜的是随着研究的深入,越来越多的手段可以用于治疗糖尿病。本文试对口服降糖药的进展做一简要的介绍。 相似文献